Investors Scrutinize Disc Medicine Following FDA Rejection

The regulatory setback occurred when the U.S. Food and Drug Administration issued a Complete Response Letter to Disc Medicine. Regulators declined to approve the company’s new drug application, citing significant uncertainties that require additional clinical evidence. This rejection effectively stalled the bitopertin program and wiped out a substantial portion of shareholder value in a single trading session.

Rosen Law is now soliciting potential plaintiffs for a prospective class action lawsuit to recover losses. Investors who purchased securities before the announcement may be eligible for compensation under a contingency fee arrangement, which excludes out-of-pocket costs. Those interested in participating in the litigation are directed to contact Phillip Kim at the firm’s New York office or submit documentation through their online portal.